The comparison of the effectiveness and safety of drospirone ethinyl estradiol and ethinyl estradiol cyproterone in the treatment of polycystic ovarian syndrome: A protocol for systematic review and meta-analysis.

Abstract

BACKGROUND:

Polycystic ovarian syndrome (PCOS) is an endocrine disorder syndrome with reproductive dysfunction and abnormal glucose metabolism. Persistent non-ovulation, excessive androgens and insulin resistance are important features and they are the most common causes of menstrual disorders in women during childbearing years. At present, the cause of PCOS is not clinically clear. Current studies suggest that it may be due to the interaction of certain genetic genes with environmental factors. It is an important cause of infertility or early miscarriage with the characteristics of various causes and complex clinical manifestations. At present, for the treatment of PCOS patients, clinical treatment mainly includes hypoglycemia, insulin and menstrual regulation and other symptomatic and supportive treatment. Drospirone ethinyl estradiol and ethinyl estradiol cyproterone are 2 of the most commonly used drugs in clinical treatment of PCOS, but there is lack of the evidence of evidence-based medicine. Therefore, this study systematically evaluates the therapeutic effect and safety of PCOS patients with 2 short-acting oral contraceptives, drospirone ethinyl estradiol and ethinyl estradiol cyproterone, which provides the guidance for clinically selecting the appropriate drug to treat PCOS.

METHODS:

Searching CNKI, WanFang Data, VIP, SinoMed, PubMed, EMbase, Web of Science, and The Cochrane Library database by computer, collecting the randomized controlled studies of DEE and EEC in the treatment of PCOS. The retrieval time limit is from the establishment of each database to July 1, 2020. In addition, tracing the references incorporated into the literature to supplement to the relevant literature. Using the retrieval method by combining the free words and the subject words, and the individual search of different databases is carried out. Meta-analysis is performed using RevMan 5.3 software after 2 researchers independently screens the literature, extracts the data, and evaluates the bias risk included in the study.

RESULTS:

This study will systematically evaluate the DEE and EEC in the treatment of PCOS by collecting the required evidence to understand the effects of the 2 drugs on hypersotrophicemia, insulin resistance, lipid metabolism, and the safety during drug use in patients of this class, and the results will be published in highly influential academic journals.

CONCLUSION:

The results of this study will provide theoretical basis for the drug treatment of polycystic ovarian syndrome and provide help in the decision-making of clinical treatment of the disease.

ETHICS AND DISSEMINATION:

In this study, meta-analysis was used to conduct a second study on the published literature. Therefore, this type of systematic review research does not need to be approved by ethics.

OSF REGISTRATION DOI:

10.17605/OSF.IO/8GW9M.

• Authors: Zhimin Liu, Ying Song, Yuanfang Xu, Jing Wang, Hongyuan Hu, Yingchun Weng
• Journal: Medicine (Medicine (Baltimore)) Vol. 99 Issue 51 Pg. e23811 (Dec 18 2020) ISSN: 1536-5964 [Electronic] United States
• PMID: 33371158 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Androstenes
• Contraceptives, Oral
• drospirenone and ethinyl estradiol combination
• Ethinyl Estradiol

Topics

• Adult
• Androstenes (standards, therapeutic use)
• Contraceptives, Oral (standards, therapeutic use)
• Ethinyl Estradiol (standards, therapeutic use)
• Female
• Humans
• Meta-Analysis as Topic
• Polycystic Ovary Syndrome (drug therapy)
• Systematic Reviews as Topic
• Treatment Outcome